ARS Pharmaceuticals, Inc. Stock Analysis & AI Score
ARS Pharmaceuticals, Inc. (SPRY) has an ST Score of 22.0 (D+), driven by its Forecast (A) and held back by its Sentiment (F). Analysts rate it Hold with a $20.00 price target (+381.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
ARS Pharmaceuticals, Inc. (SPRY) has an ST Score of 22.0 (D+), driven by its Forecast (A) and held back by its Sentiment (F). Analysts rate it Hold with a $20.00 price target (+381.9% upside).
- Strongest
- ForecastA
- Weakest
- SentimentF
All factor grades
- ForecastA
- GrowthC-
- ValuationD
- Financial StrengthD
- MomentumD-
- ProfitabilityF
- SentimentF
- Piotroski2/9
Contact
SPRY stock: frequently asked questions
What is SPRY's ST Score?
ARS Pharmaceuticals, Inc. (SPRY) has an ST Score of 22.0 (D+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SPRY a buy, hold, or sell?
Analysts rate SPRY a Hold, with a price target of $20.00 (+381.9% vs the current price). Our ST Score grades it D+ (22.0/100). The ST Score is a data-driven signal, not a recommendation.
What are SPRY's factor grades?
Valuation D, Profitability F, Financial Strength D, Momentum D-, Growth C-, Forecast A, Sentiment F.
What is SPRY's valuation grade?
ARS Pharmaceuticals, Inc. (SPRY) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SPRY's growth grade?
ARS Pharmaceuticals, Inc. (SPRY) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SPRY's profitability grade?
ARS Pharmaceuticals, Inc. (SPRY) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SPRY's financial strength grade?
ARS Pharmaceuticals, Inc. (SPRY) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SPRY?
The average analyst price target for ARS Pharmaceuticals, Inc. (SPRY) is $20.00 from 10 analysts, which is +381.9% versus the recent price of $4.15.
What is SPRY's Piotroski score?
ARS Pharmaceuticals, Inc. (SPRY) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.